Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Transcriptional control of leukemogenesis by the chromatin reader SGF29

Blood (2024) 143 (8): 697–712.

https://doi.org/10.1182/blood.2023021234

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Blood (2023) 141 (9): 1023–1035.

https://doi.org/10.1182/blood.2021015246

Published: 2023

Includes: Supplemental data

Journal Articles

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias

Blood (2023) 141 (8): 955–960.

https://doi.org/10.1182/blood.2022016411

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Daniel Bergér, Steffen Dickopf, Binje Vick, Katharina Weinlich, Irmela Jeremias, Ulrich Brinkmann, Christoph Klein

Blood (2022) 140 (Supplement 1): 2249–2250.

https://doi.org/10.1182/blood-2022-163104

Published: 2022

Journal Articles

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

Sebastian E. Koschade, Kevin Klann, Shabnam Shaid, Binje Vick, Jan A. Stratmann, Marlyn Thölken, Laura M. Meyer, The Duy Nguyen, Julia Campe, Laura M. Moser, Susanna Hock, Fatima Baker, Christian Meyer, Frank Wempe, Hubert Serve, Evelyn Ullrich, Irmela Jeremias, Christian Münch, Christian H. Brandts

Blood (2022) 140 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2022-168824

Published: 2022

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Ehsan Bahrami, Jan Philipp Schmid, Martin Becker, Anna-Katharina Wirth, Rupert Öllinger, Roland Rad, Binje Vick, Ashok Kumar Jayavelu, Matthias Mann, Tobias Herold, Irmela Jeremias

Blood (2021) 138 (Supplement 1): 708.

https://doi.org/10.1182/blood-2021-149658

Published: 2021

Journal Articles

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2021-148429

Published: 2021

Journal Articles

WT1 and DNMT3A Play an Essential Function and Represent Therapeutic Vulnerabilities in Certain AML Samples, As Shown By CRISPR/Cas9 Mediated Knockout in PDX Models In Vivo

Maryam Ghalandary, Yuqiao Gao, Martin Becker, Diana Amend, Klaus H. Metzeler, Maja Rothenberg-Thurley, Irmela Jeremias

Blood (2021) 138 (Supplement 1): 377.

https://doi.org/10.1182/blood-2021-150305

Published: 2021

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Dana Stenger, Tanja A. Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G. P. Grünewald, Sebastian Kobold, Dirk H. Busch, Irmela Jeremias, Franziska Blaeschke, Tobias Feuchtinger

Blood (2020) 136 (12): 1407–1418.

https://doi.org/10.1182/blood.2020005185

Published: 2020

Includes: Supplemental data

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo

Ehsan Bahrami, PhD, Martin Becker, PhD, Anna-Katharina Wirth, MSc, Jan Phillip Schmid, MSc, Tobias Herold, MD, Rupert Öllinger, PhD, Roland Rad, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 3945.

https://doi.org/10.1182/blood-2019-124288

Published: 2019

Journal Articles

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Christina Maria Zeller, MSc, Daniel Richter, MSc, Binje Vick, PhD, Tobias Herold, MD, Johannes Bagnoli, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Wolfgang Enard, PhD, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 1450.

https://doi.org/10.1182/blood-2019-127867

Published: 2019

Journal Articles

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Blood (2019) 134 (3): 263–276.

https://doi.org/10.1182/blood.2018862383

Published: 2019

Includes: Supplemental data

Journal Articles

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Sophie M. Stief, M.Sc., Anna-Li Hanneforth, Raphael Mattes, Sabrina Weser, M.Sc., Binje Vick, PhD, Michael D. Bartoschek, M.Sc., Helena Domínguez Moreno, M.Sc., Wen-Hsin Liu, PhD, Bianka Ksienzyk, Maja Rothenberg-Thurley, PhD, Hilmar Quentmeier, PhD, Wolfgang Hiddemann, Klaus H. Metzeler, MD, Gunnar Schotta, PhD, Sebastian Bultmann, PhD, Irmela Jeremias, MD PhD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD

Blood (2018) 132 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2018-99-114959

Published: 2018

Journal Articles

The Nucleotide Kinase Nadk Is Required for ROS Detoxification and Constitutes a Metabolic Vulnerability of NOTCH1-Driven T-ALL

Etienne De Braekeleer, PhD MSc, Joanne Hsu, BS, Celine Hervieu, MSc, Konstantinos Tzelepis, PhD, Stefano Indraccolo, MD, Alan J. Warren, PhD FRCP, FRCPath, Irmela Jeremias, MD PhD, David Fernandez Antoran, PhD, Phil H Jones, PhD, Margaret A. Goodell, PhD, George S. Vassiliou

Blood (2018) 132 (Supplement 1): 2615.

https://doi.org/10.1182/blood-2018-99-118827

Published: 2018

Journal Articles

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, PhD MSc, Fotini Vogiatzi, PhD, Michela Carlet, PhD, Christian Vokuhl, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Irmela Jeremias, MD PhD, Stephan Fuhrmann, MD, Elias Hobeika, PhD, Hassan Jumaa, Prof. Dr., Ameera Alsadeq, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 386.

https://doi.org/10.1182/blood-2018-99-114595

Published: 2018

NARROW

Transcriptional control of leukemogenesis by the chromatin reader SGF29

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

WT1 and DNMT3A Play an Essential Function and Represent Therapeutic Vulnerabilities in Certain AML Samples, As Shown By CRISPR/Cas9 Mediated Knockout in PDX Models In Vivo

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

The Nucleotide Kinase Nadk Is Required for ROS Detoxification and Constitutes a Metabolic Vulnerability of NOTCH1-Driven T-ALL

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only